financetom
Business
financetom
/
Business
/
Salesforce beats quarterly revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce beats quarterly revenue estimates
Sep 3, 2025 1:27 PM

(Reuters) -Salesforce ( CRM ) beat second-quarter revenue estimates on Wednesday, fueled by steady demand for its Agentforce platform and enterprise software products, and announced a $20 billion increase to its existing share buyback program.

The cloud software provider's increase in the share repurchase program brings the total to $50 billion.

Salesforce ( CRM ) has adopted artificial intelligence on a wide scale, integrating it into the various cloud services and creating an AI agent platform to automate tasks in a bid to streamline operations and boost margins.

The company's revenue for the quarter was $10.24 billion, compared with the analysts' average expectation of $10.14 billion, according to data compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China tells tech firms to stop buying Nvidia's AI chips, FT reports
China tells tech firms to stop buying Nvidia's AI chips, FT reports
Sep 17, 2025
Sept 17 (Reuters) - China's internet regulator has ordered top technology firms to halt purchases of Nvidia ( NVDA ) artificial intelligence chips and cancel existing orders as part of a broader push to cut reliance on U.S. technology, the Financial Times reported on Wednesday. Shares of the US company were down 1% in premarket trading. Successive U.S. administrations have...
Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership
Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership
Sep 17, 2025
Co-Diagnostics Inc. ( CODX ) shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data. Check out the current price of CODX stock here. Strategic Partnership Fails to Sustain Momentum The molecular diagnostics firm revealed it has signed a Memorandum of Understanding...
Eli Lilly Says Phase 3 Study of Orforglipron Meets Primary Endpoint
Eli Lilly Says Phase 3 Study of Orforglipron Meets Primary Endpoint
Sep 17, 2025
05:22 AM EDT, 09/17/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that a phase 3 study of orforglipron met its primary endpoint, with all three doses of orforglipron demonstrating superior body weight reduction compared with placebo. Orforglipron is the company's investigational oral glucagon-like peptide-1, or GLP-1, receptor agonist and the phase 3 study enrolled adults with obesity,...
Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill
Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill
Sep 17, 2025
VIENNA (Reuters) - Eli Lilly's ( LLY ) international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration's new fast-track review process for its experimental weight-loss pill orforglipron. There is very little knowledge about this national priority voucher today. I would not assume we will submit with a national...
Copyright 2023-2026 - www.financetom.com All Rights Reserved